Glycogen Synthase Kinase-3 (GSK3) in Psychiatric Diseases and Therapeutic Interventions

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|7|11|1421-1434

ISSN： 1389-4501

Source： Current Drug Targets, Vol.7, Iss.11, 2006-11, pp. : 1421-1434

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Possible Involvement of Glycogen Synthase Kinase-3 (GSK-3) in Diabetes, Cancer and Central Nervous System Diseases

By  

Current Pharmaceutical Design, Vol. 17, Iss. 22, 2011-07 ,pp. : 2264-2277

Bentham Science Publishers

Access to resources Recommend Favorite

Glycogen Synthase Kinase-3 (GSK-3) Inhibitors for the Treatment of Alzheimer's Disease

By  

Current Pharmaceutical Design, Vol. 16, Iss. 25, 2010-08 ,pp. : 2790-2798

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting glycogen synthase kinase-3 (GSK-3) in the treatment of Type 2 diabetes

By MacAulay Katrina   Woodgett James R  

Expert Opinion on Therapeutic Targets, Vol. 12, Iss. 10, 2008-10 ,pp. : 1265-1274

Informa Healthcare

Access to resources Recommend Favorite

Glycogen synthase kinase-3 – a promising therapeutic target: interview with Hagit Eldar-Finkelman

By Quigley Emma  

Expert Opinion on Therapeutic Targets, Vol. 10, Iss. 2, 2006-04 ,pp. : 199-201

Informa Healthcare

Access to resources Recommend Favorite

Physiological Roles of Glycogen Synthase Kinase-3: Potential as a Therapeutic Target for Diabetes and Other Disorders

By  

Current Drug Targets - Immune, Endocrine & Metabolic Disorders, Vol. 3, Iss. 4, 2003-12 ,pp. : 281-290

Bentham Science Publishers

Access to resources Recommend Favorite